BACKGROUND: Preexisting antibodies to influenza, shaped by early infection and subsequent exposures, may impact responses to influenza vaccination. METHODS: We enrolled 72 children (aged 7-17 years) in 2015-2016; all received inactivated influenza vaccines. Forty-one were also vaccinated in 2014-2015, with 12 becoming infected with A(H3N2) in 2014-2015. Thirty-one children did not have documented influenza exposures in the prior 5 seasons. Sera were collected pre- and postvaccination in both seasons. We constructed antibody landscapes using hemagglutination inhibition antibody titers against 16 A(H3N2) viruses representative of major antigenic clusters that circulated between 1968 and 2015. RESULTS: The breadth of the antibody landscapes increased with age. Vaccine-induced antibody responses correlated with boosting of titers to previously encountered antigens. Postvaccination titers were the highest against vaccine antigens rather than the historic A(H3N2) viruses previously encountered. Prevaccination titers to the vaccine were the strongest predictors of postvaccination titers. Responses to vaccine antigens did not differ by likely priming virus. Influenza A(H3N2)-infected children in 2014-2015 had narrower antibody landscapes than those uninfected, but prior season infection status had little effect on antibody landscapes following 2015-2016 vaccination. CONCLUSIONS: A(H3N2) antibody landscapes in children were largely determined by age-related immune priming, rather than recent vaccination or infection. Published by Oxford University Press for the Infectious Diseases Society of America 2020.
BACKGROUND: Preexisting antibodies to influenza, shaped by early infection and subsequent exposures, may impact responses to influenza vaccination. METHODS: We enrolled 72 children (aged 7-17 years) in 2015-2016; all received inactivated influenza vaccines. Forty-one were also vaccinated in 2014-2015, with 12 becoming infected with A(H3N2) in 2014-2015. Thirty-one children did not have documented influenza exposures in the prior 5 seasons. Sera were collected pre- and postvaccination in both seasons. We constructed antibody landscapes using hemagglutination inhibition antibody titers against 16 A(H3N2) viruses representative of major antigenic clusters that circulated between 1968 and 2015. RESULTS: The breadth of the antibody landscapes increased with age. Vaccine-induced antibody responses correlated with boosting of titers to previously encountered antigens. Postvaccination titers were the highest against vaccine antigens rather than the historic A(H3N2) viruses previously encountered. Prevaccination titers to the vaccine were the strongest predictors of postvaccination titers. Responses to vaccine antigens did not differ by likely priming virus. Influenza A(H3N2)-infected children in 2014-2015 had narrower antibody landscapes than those uninfected, but prior season infection status had little effect on antibody landscapes following 2015-2016 vaccination. CONCLUSIONS: A(H3N2) antibody landscapes in children were largely determined by age-related immune priming, rather than recent vaccination or infection. Published by Oxford University Press for the Infectious Diseases Society of America 2020.
Authors: Danuta M Skowronski; Catharine Chambers; Gaston De Serres; Suzana Sabaiduc; Anne-Luise Winter; James A Dickinson; Jonathan B Gubbay; Kevin Fonseca; Steven J Drews; Hugues Charest; Christine Martineau; Mel Krajden; Martin Petric; Nathalie Bastien; Yan Li; Derek J Smith Journal: J Infect Dis Date: 2017-04-01 Impact factor: 5.226
Authors: Jiwon Lee; Philipp Paparoditis; Andrew P Horton; Alexander Frühwirth; Jonathan R McDaniel; Jiwon Jung; Daniel R Boutz; Dania A Hussein; Yuri Tanno; Leontios Pappas; Gregory C Ippolito; Davide Corti; Antonio Lanzavecchia; George Georgiou Journal: Cell Host Microbe Date: 2019-02-19 Impact factor: 21.023
Authors: Willem Luytjes; Vincent Enouf; Maarten Schipper; Karlijn Gijzen; Wai Ming Liu; Mariken van der Lubben; Adam Meijer; Sylvie van der Werf; Ernst C Soethout Journal: Vaccine Date: 2012-06-09 Impact factor: 3.641
Authors: Huong Q McLean; Herve Caspard; Marie R Griffin; Manjusha Gaglani; Timothy R Peters; Katherine A Poehling; Christopher S Ambrose; Edward A Belongia Journal: JAMA Netw Open Date: 2018-10-05
Authors: Jens Wrammert; Kenneth Smith; Joe Miller; William A Langley; Kenneth Kokko; Christian Larsen; Nai-Ying Zheng; Israel Mays; Lori Garman; Christina Helms; Judith James; Gillian M Air; J Donald Capra; Rafi Ahmed; Patrick C Wilson Journal: Nature Date: 2008-04-30 Impact factor: 49.962
Authors: Mark G Thompson; Allison Naleway; Alicia M Fry; Sarah Ball; Sarah M Spencer; Sue Reynolds; Sam Bozeman; Min Levine; Jacqueline M Katz; Manjusha Gaglani Journal: Vaccine Date: 2016-02-10 Impact factor: 3.641
Authors: Huong Q McLean; Jennifer P King; Pamela Talley; Brendan Flannery; Sarah Spencer; Min Z Levine; Thomas C Friedrich; Edward A Belongia Journal: J Pediatric Infect Dis Soc Date: 2020-04-30 Impact factor: 3.164
Authors: Katherine V Williams; Bo Zhai; John F Alcorn; Mary Patricia Nowalk; Min Z Levine; Sara S Kim; Brendan Flannery; Krissy Moehling Geffel; Amanda Jaber Merranko; Jennifer P Nagg; Mark Collins; Michael Susick; Karen S Clarke; Richard K Zimmerman; Judith M Martin Journal: Vaccine Date: 2021-12-21 Impact factor: 3.641